Effect of Empagliflozin on NT-Pro Brain Natriuretic Peptide in Heart Failure Patients With Reduced Ejection Fraction
Heart Failure With Reduced Ejection Fraction
About this trial
This is an interventional treatment trial for Heart Failure With Reduced Ejection Fraction focused on measuring Empagliflozin, Heart failure with reduced ejection fraction, Nt-proBNP
Eligibility Criteria
Inclusion Criteria: Chronic heart failure with mildly reduced ejection fraction (41-49%) and reduced ejection fraction (≤40%) 18-70 years Not receiving empagliflozin or any SGLT2 inhibitor Elevated plasma NT-proBNP (≥125 pg/ml) eGFR ≥ 20 ml/min/1.73m2 Exclusion Criteria: Acute Coronary Syndrome (ACS) Pulmonary embolism Myocarditis Valvular heart disease Hypertrophic or restrictive cardiomyopathy Congenital heart disease Pulmonary hypertension Surgical procedures involving the heart Heart contusion Cardioversion, Implantable Cardioverter Defibrillator (ICD) shock Patients receiving digoxin Advanced age (>70years) Ischemic stroke Chronic Obstructive Pulmonary Disease Subarachnoid haemorrhage Severe infection (including pneumonia and sepsis) Anemia Renal dysfunction (eGFR <20ml/min/1.73m2) Liver dysfunction (mainly liver cirrhosis with ascites- Child Pugh B & C) Severe burns Paraneoplastic syndrome Severe metabolic and hormone abnormalities (e.g thyrotoxicosis, diabetic ketosis)
Sites / Locations
- Alexandria UniversityRecruiting
Arms of the Study
Arm 1
Other
Heart failure patients with reduced and mildly reduced ejection fraction
One paired test group described as Heart Failure patients with reduced and mildly reduced ejection fraction are indicated for Empagliflozin. Blood samples will be collected as a baseline before Empagliflozin administration to test for N-terminal Pro-B-type Natriuretic Peptide, Followed by administration of empagliflozin for 6 months. Then retest the N-terminal Pro-B-type Natriuretic Peptide after 6 months.